- Home
- NTHI vs NVCT Comparison
NTHI vs NVCT Comparison
Compare NTHI & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTHI | NVCT |
|---|---|---|
| Founded | 2008 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.5M | 220.0M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | NTHI | NVCT |
|---|---|---|
| Price | $11.08 | $8.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.33 |
| AVG Volume (30 Days) | ★ 71.2K | 58.0K |
| Earning Date | 02-23-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $59,990.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.20 | $5.55 |
| 52 Week High | $25.00 | $11.52 |
Technical Indicators
Market Signals| Indicator | NTHI | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 64.35 | 56.82 |
| Support Level | $9.05 | $8.08 |
| Resistance Level | $11.31 | $9.22 |
| Average True Range (ATR) | 1.15 | 0.46 |
| MACD | 0.17 | -0.01 |
| Stochastic Oscillator | 80.93 | 65.07 |
Price Performance
Historical ComparisonAbout NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.